Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 9/20 | 0.39 |
| ▸ | HTR2B | P41595 | 6/20 | 0.39 |
| ▸ | HTR2A | P28223 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10675972 | 1.00 | MEN1 (0.42) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL10676736 | 1.00 | MEN1 (0.42) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL10676739 | 1.00 | MEN1 (0.42) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL10675977 | 1.00 | MEN1 (0.42) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL10676981 | 0.82 | MEN1 (0.42) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL10669028 | 0.82 | MEN1 (0.42) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL10676988 | 0.82 | MEN1 (0.42) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL10669021 | 0.82 | MEN1 (0.42) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL10669034 | 0.82 | MEN1 (0.42) | MEN1KMT2AHTR2CHTR2BHTR2A | |
| SCHEMBL25254330 | 0.79 | HTR2C (0.57) | HTR2CHTR2BHTR2AMAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050282817-A1 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity | NOKIA CORPORATION (FI) | 2005-12-22 | — | — | US | disclosed |
| WO-1999031077-A1 | ARYLPIPERAZINES HAVING ACTIVITY AT THE SEROTONIN 1A RECEPTOR | ELI LILLY AND COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
| US-4736057-A | Cyclohexane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-04-05 | — | — | US | disclosed |
| EP-0142322-B1 | CYCLOHEXANE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-09 | — | — | EP | disclosed |
| EP-0142322-A2 | Cyclohexane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282817-A1 | 4-(3-Phenyl-3-carbocycloylpropyl)-1-phenyl- or pyridylpiperazine derivatives: 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine oxalate; serotonin receptor antagonists; obesity | HTR3A, HTR3C, HTR1A | MEN1 4759/4885KMT2A 2605/4885HTR2C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.